1296 RESULTS
CONFERENCE COVERAGE 2024-09-19 Conference Coverage Alzheimer’s is a multifaceted disease, particularly in its sporadic, late-onset form. Myriad factors—genetics, environment, cardiovascular health, metabolism, and inflammation—contribute to a decades-long process. Generating animal mod
CONFERENCE COVERAGE 2024-09-04 Conference Coverage Ever since variants in the gene for TMEM106b were tied to frontotemporal dementia, Alzheimer’s, and other neurodegenerative diseases, this endolysosomal protein has been a head-scratcher for scientists. Its ability to surprise is exemp
CONFERENCE COVERAGE 2024-08-30 Conference Coverage As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association International Conference, held last month
CONFERENCE COVERAGE 2024-08-28 Conference Coverage The brain shrinkage seen on amyloid immunotherapy remains an unsolved and concerning riddle. At the Alzheimer’s Association International Conference, held July 27 to August 1 in Philadelphia, Nick Fox of University College London offer
CONFERENCE COVERAGE 2024-08-09 Conference Coverage Among the hundreds of studies presented at this year’s Alzheimer’s Association International Conference, held July 27 to August 1 in Philadelphia, one of the few that made a splash in the news was not news at all. Perhaps spurred by a
CONFERENCE COVERAGE 2024-04-19 Conference Coverage Microglia seem to play a hand in every aspect of Alzheimer’s pathogenesis, from the seeding and clearing of plaques to the traveling of tau to the dying of neurons. Scientists are pursuing therapeutics that both promote their neuroprot
CONFERENCE COVERAGE 2024-04-12 Conference Coverage As neuronal supporters and immune surveyors, astrocytes and microglia are no mere bystanders to the neuronal mayhem that unfolds in Alzheimer’s disease. At the AD/PD meeting, held March 5-9 in Lisbon, scientists presented new twists on
CONFERENCE COVERAGE 2024-04-12 Conference Coverage Scientists are expanding strategies for targeting misfolded tau. At this year’s AD/PD conference, held March 5 to 9 in Lisbon, Portugal, speakers highlighted a protein modification approach—sumoylation. This post-translational modifica
CONFERENCE COVERAGE 2022-06-29 Conference Coverage Part 2 of 2 Frontotemporal dementia is a wildly heterogeneous group of disorders, and many people with an FTD have difficulty getting an accurate diagnosis, let alone proper care or treatment. Digital biomarkers would expand access to
CONFERENCE COVERAGE 2022-06-28 Conference Coverage Part 1 of 2 Kristin Holloway opened the inaugural Holloway Summit, held May 18-20 in Miami, by recounting her family’s experience with frontotemporal dementia (FTD). The events leading up to the diagnosis of her husband, Lee, may seem
CONFERENCE COVERAGE 2022-04-09 Conference Coverage Current treatments for Parkinson’s only address the disease's symptoms, and much like Alzheimer's scientists are pursuing that disease's central pathogenic proteins, Parkinson's scientists believe that targeting α-s
CONFERENCE COVERAGE 2022-04-09 Conference Coverage Hundreds, if not thousands, of transcripts and proteins get up- or downregulated in Alzheimer’s disease, but how this broadly affects the brain remains a mystery. Scientists are trying to solve it by simultaneously isolating millions o
CONFERENCE COVERAGE 2022-04-02 Conference Coverage Known as first responders to viral infection, Type I interferons may also play a part—for better or worse—in neurodegenerative disease. At AD/PD 2022, held March 15-20 online and in Barcelona, Spain, researchers reported that not only
CONFERENCE COVERAGE 2022-04-01 Conference Coverage Last June’s accelerated FDA approval of Aduhelm based on amyloid plaque removal left unresolved whether the antibody truly shores up cognitive function. At the 16th International Conference on Alzheimer’s and Parkinson’s Diseases, held
CONFERENCE COVERAGE 2022-03-31 Conference Coverage With several anti-amyloid antibodies now proven to clear plaque from the human brain, researchers are turning their attention to fine-tuning immunotherapy for Alzheimer’s disease. At the 16th International Conference on Alzheimer’s and
